Free Trial
NASDAQ:MIRM

Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

Mirum Pharmaceuticals logo
$74.89 -2.80 (-3.60%)
Closing price 09/10/2025 04:00 PM Eastern
Extended Trading
$74.96 +0.06 (+0.09%)
As of 09/10/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Key Stats

Today's Range
$74.24
$77.96
50-Day Range
$49.93
$77.69
52-Week Range
$36.86
$78.10
Volume
409,582 shs
Average Volume
778,606 shs
Market Capitalization
$3.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.13
Consensus Rating
Buy

Company Overview

Mirum Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

MIRM MarketRank™: 

Mirum Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 375th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Mirum Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Mirum Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Mirum Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.43) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mirum Pharmaceuticals is -61.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mirum Pharmaceuticals is -61.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mirum Pharmaceuticals has a P/B Ratio of 15.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mirum Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    13.79% of the outstanding shares of Mirum Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Mirum Pharmaceuticals has recently increased by 4.52%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Mirum Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Mirum Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.79% of the outstanding shares of Mirum Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Mirum Pharmaceuticals has recently increased by 4.52%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Mirum Pharmaceuticals has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Mirum Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,320,624.00 in company stock.

  • Percentage Held by Insiders

    14.36% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Mirum Pharmaceuticals' insider trading history.
Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MIRM Stock News Headlines

A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
See More Headlines

MIRM Stock Analysis - Frequently Asked Questions

Mirum Pharmaceuticals' stock was trading at $41.35 on January 1st, 2025. Since then, MIRM stock has increased by 81.1% and is now trading at $74.89.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.19. The business's quarterly revenue was up 64.1% on a year-over-year basis.
Read the conference call transcript
.

Mirum Pharmaceuticals (MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Mirum Pharmaceuticals' top institutional investors include BVF Inc. IL (5.50%), Eventide Asset Management LLC (5.25%), State Street Corp (2.74%) and Geode Capital Management LLC (2.08%). Insiders that own company stock include Niall O'donnell, Patrick J Heron, Christopher Peetz, Lara Longpre, Pamela Vig, Peter Radovich, Eric Bjerkholt, Joanne Quan, Jolanda Howe, Michael G Grey and Saira Ramasastry.
View institutional ownership trends
.

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Last Earnings
8/06/2025
Today
9/10/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MIRM
CIK
1759425
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

High Price Target
$89.00
Low Price Target
$49.00
Potential Upside/Downside
-1.0%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$87.94 million
Net Margins
-13.65%
Pretax Margin
-13.37%
Return on Equity
-24.76%
Return on Assets
-8.50%

Debt

Debt-to-Equity Ratio
1.21
Current Ratio
3.13
Quick Ratio
2.97

Sales & Book Value

Annual Sales
$336.89 million
Price / Sales
11.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.70 per share
Price / Book
15.93

Miscellaneous

Outstanding Shares
50,240,000
Free Float
43,024,000
Market Cap
$3.76 billion
Optionable
Optionable
Beta
0.92

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:MIRM) was last updated on 9/11/2025 by MarketBeat.com Staff
From Our Partners